Investors’ bearish sentiment that further testing of the clinical
utility of Progenics Pharma’s (PGNX-$5.00)
PSMA-ADC might be pointless due to toxicity concerns is unfounded: Robert
Israel, MD, one of the study authors and executive vice president of medical
affairs at Progenics, pointed out to Medscape
Medical News that both of the patients who died had predisposing
conditions.
"One had an indwelling central line [known to increase risk
of developing sepsis] and the other had repeated urinary tract
infections," said Dr. Israel. "The patients were also heavily
pretreated and didn't have much in the way of other options."
As a new class of biological therapeutics, the ADC market is still
in its infancy. Nonetheless, skeptics might want to spend a Saturday reading up
on the managed benefits of these highly potent drugs in the context of
understood off-target toxicities.
See more at YCharts: 2 Deaths, 25% Plunge -- And Still A BigUpside
Editor David J Phillips does not hold a
financial interest in any stocks mentioned in this article. The 10Q Detective
has a Full Disclosure Policy.
No comments:
Post a Comment